KR840004739A - 1,3-디옥산-5-일 알케논산의 제조방법 - Google Patents

1,3-디옥산-5-일 알케논산의 제조방법 Download PDF

Info

Publication number
KR840004739A
KR840004739A KR1019830002053A KR830002053A KR840004739A KR 840004739 A KR840004739 A KR 840004739A KR 1019830002053 A KR1019830002053 A KR 1019830002053A KR 830002053 A KR830002053 A KR 830002053A KR 840004739 A KR840004739 A KR 840004739A
Authority
KR
South Korea
Prior art keywords
formula
hydroxy
compound
alkyl
compounds
Prior art date
Application number
KR1019830002053A
Other languages
English (en)
Other versions
KR880002001B1 (ko
Inventor
죠지 브루스터(외 1) 앤드류
Original Assignee
원본미기재
임페리얼 케미칼 인더스트리즈 피엘시
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 임페리얼 케미칼 인더스트리즈 피엘시 filed Critical 원본미기재
Publication of KR840004739A publication Critical patent/KR840004739A/ko
Application granted granted Critical
Publication of KR880002001B1 publication Critical patent/KR880002001B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

내용 없음

Description

1,3-디옥산-5-일 알케논산의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (1)

  1. (a) Rc가 히드록시이고 A가 비닐렌인 화합물을 위해서, 구조식(Ⅱ)의 알데히드를 구조식(Ⅲ)의 위티그시약과 반응시키며
    (Rd)3P=CH.Y.CO2M+(Ⅲ)
    여기서, Rd는(1-6c)알킬 또는 아릴이고 M+는 알카리 금속양이온; (b) Qa와 Qb의 하나는 수소이고 다른 것은 수소, 알칸설포닐, 아르네설포닐 또는 R와 R1이 같거나 또는 다른 알킬인 구조식 -CRR1의 그룹인 구조식 (ⅩⅢ)의 에리트로-디올 유도체를 구조식 RaRb·CO의 카르보닐화합물 또는 아세탈, 헤미아세탈 또는 이들의 하이드레이트와 반응시키고, (c) Rc가 히드록시인 구조식 I의 화합물을 위해, 구조식 ⅩⅥ의 알콜을 산화시키며, (d) Rc가 히드록시인 구조식 I의 화합물을 위해서, 구조식 ⅩⅦ의 화합물을 가수분해시키며, 여기서 W는 알콕시카르보닐, 페녹시카르보닐, 벤질옥시카르보닐, 시아노 또는 카르바모일; (e) Ra,Rb 또는 벤젠링 B가 히드록시 치환체인 구조식 I의 화합물을 위해서, 언급한 화합물의 상응하는 유도체를 탈보호시키며 여기서 히드록시 치환체는 트리메틸실일, (1-6c)알킬 또는 아실보호그룹에 의해 보호시킨다. (f) Ra와 Rb는 둘다 수소인 구조식 I의 화합물을 위해서, Qa와 Qb가 둘다 수소인 구조식 ⅩⅢ의 에리트로-디올을 염기존재하에 메틸렌 브로마이드와 반응시키며; 그후:Rc가(1-6c)알콕시인 구조식 I의 화합물이 요구될때, Ra가 히드록시인 구조식 I의 상응하는 산 또는 이들의 반응성유도체를 종래 진행을 사용하여 에스테르화시키며; Rc가(1-6c)알칸 설폰아미도인 구조식 I의 화합물이 요구될때, Rc가 히드록시인 구조식 I의 상응하는 산을 탈수제 존재하에 적합한(1-6c)알칸설폰아미드와 반응시키거나 또는 구조식 I의 언급한 산의 반응성유도체를 적합한(1-6c)알칸설폰아미드 또는 이들의 알카리금속염과 반응시키며; A가 에틸렌인 구조식 I의 화합물이 요구될때, A가 비닐렌인 구조식 I의 상응하는 화합물을 촉매존재하에서 수첨시킨다. Rc가 히드록시인 구조식 I화합물의 염이 요구될때, 언급한 화합물을 적합한 염기와 반응시켜 생리학적으로 허용될 수 있는 양이온을 얻고 구조식 I화합물의 광학적으로 활성형태가 요구될때, 이미 언급한 진행중 하나는 광학적으로 활성 출발물질을 사용하여 수행하거나 또는 Rc가 히드록시인 구조식 I화합물의 라세믹 형태를 적합한 유기염기의 광학적으로 활성형태로 반응시키며 이렇게 얻어진 염의 입체이성체 혼합물의 분리와 Rc와 히드록시와 다른것일때, 이미 언급한 바와 같이 에스테르화 또는 아미드화에 의해 처리된 산으로 처리하여 구조식I의 언급한 화합물의 광학적으로 활성형태의 유리에 의해 수행하는 것을 특징으로하는 구조식 I의 화합물 또는 이들의 염을 제조하는 방법.
    여기서, Ra와 Rb는 독립적으로 수소(2-6c)알켄일, (1-8c)알킬임의로 3이상 할로겐 치환체, 펜타플루오로페닐, 아릴 또는 아릴(1-4c)알킬이며 후자의 둘은 임의로 할로게노, (1-6c)알킬, (1-6c)알콕시, (1-6c)알콕시, (1-4c)알켄디옥시, 트리플루오로메틸, 시아노, 니트로, 히드록시, (2-6c)알카노일옥시, (1-6c)알킬티오, (1-6c)알칸설포닐, (1-6c)알카노일아미노와 탄소원자 2내지 4의 옥사폴리메틸렌으로 부터 선택된 3이상 치환체를 나타낼 수 있으며 두 Ra와 Rb가 알킬 또는 알켄일일때, Ra와 Rb에서 탄소원자의 전체수는 함께 8또는 그 이하이거나 또는 Ra와 Rb는 함께 탄소원자 2내지 7의 폴리메틸렌을 형성하며 임의로 하나 또는 둘(1-4c)알킬 치환체를 나타내며; Rc는 히드록시, (1-6c)알콕시 또는 (1-6c)알칸설폰아미드; n은 정수 1 또는 2; A는 에틸렌 또는 비닐렌; Y는 임의로 치환체로서(1-4c)알킬을 나타내는 탄소원자 2내지 5의 폴리메틸렌; 벤젠링 B는 임의로 할로게노, (1-6c)알킬, (1-6c)알콕시, 히드록시, (2-6c)알카노일옥시, (1-6c)알카노일아미노, 트리플루오로메틸과 니트로로 부터 선택된 하나 또는 둘치환체를 나타내고 디옥산링의 4와 5위치에서 치환체는 식스-상대적 스테레오 키미스트리를 갖거나, 또는 Rc가 히드록시인 이들 화합물을 위해서, 염과 이들의 염을 생리학적으로 허용될 수 있는 양이온을 얻는다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019830002053A 1982-05-12 1983-05-12 1,3-디옥산-5-일 알케논산의 제조방법 KR880002001B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB8213702 1982-05-12
GB8213702 1982-05-12
GB838310407A GB8310407D0 (en) 1982-05-12 1983-04-18 1 3 - dioxan -5- ylalkenoic acids
GB8310407 1983-04-18

Publications (2)

Publication Number Publication Date
KR840004739A true KR840004739A (ko) 1984-10-24
KR880002001B1 KR880002001B1 (ko) 1988-10-11

Family

ID=10530304

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019830002053A KR880002001B1 (ko) 1982-05-12 1983-05-12 1,3-디옥산-5-일 알케논산의 제조방법

Country Status (32)

Country Link
US (3) US4567197A (ko)
EP (1) EP0094239B1 (ko)
JP (1) JPS58222081A (ko)
KR (1) KR880002001B1 (ko)
AR (1) AR240817A1 (ko)
AT (1) ATE28329T1 (ko)
AU (1) AU562056B2 (ko)
CA (4) CA1258464A (ko)
CS (2) CS245795B2 (ko)
CY (1) CY1453A (ko)
DD (2) DD219769A5 (ko)
DE (1) DE3372483D1 (ko)
DK (1) DK163431C (ko)
ES (4) ES8407038A1 (ko)
FI (1) FI80027C (ko)
GB (1) GB8310407D0 (ko)
GR (1) GR78138B (ko)
HK (1) HK17889A (ko)
HU (1) HU198705B (ko)
IE (1) IE55114B1 (ko)
IL (1) IL68628A0 (ko)
KE (1) KE3823A (ko)
MW (1) MW1583A1 (ko)
NO (1) NO162383B (ko)
NZ (1) NZ204202A (ko)
PH (1) PH21691A (ko)
PL (3) PL140463B1 (ko)
PT (1) PT76684B (ko)
SG (1) SG57088G (ko)
SU (1) SU1277893A3 (ko)
ZA (1) ZA833179B (ko)
ZW (1) ZW10083A1 (ko)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8310407D0 (en) * 1982-05-12 1983-05-25 Ici Plc 1 3 - dioxan -5- ylalkenoic acids
FR2551446B1 (fr) * 1983-08-31 1987-03-20 Elf Aquitaine Compositions de resines ayant une resistance amelioree au choc renfermant un polymere thermoplastique, un additif choc du type copolymere greffe, et eventuellement d'autres additifs, et copolymere greffe correspondant, a caractere d'additif choc
GB8330094D0 (en) * 1983-11-11 1983-12-21 Ici Plc Diphenyl compounds
GB8330120D0 (en) * 1983-11-11 1983-12-21 Ici Plc Chemical process
GB8330097D0 (en) * 1983-11-11 1983-12-21 Ici Plc Cyclic ethers
GB8417314D0 (en) * 1984-07-06 1984-08-08 Ici Plc Carboxylic acid derivatives
GB8511895D0 (en) * 1985-05-10 1985-06-19 Ici Plc Heterocyclic compounds
GB8511891D0 (en) * 1985-05-10 1985-06-19 Ici Plc Alkenoic acids
EP0201352B1 (en) * 1985-05-10 1992-06-24 Imperial Chemical Industries Plc Alkene derivatives
GB8511892D0 (en) * 1985-05-10 1985-06-19 Ici Plc Fluoralkane derivatives
GB8511890D0 (en) * 1985-05-10 1985-06-19 Ici Plc Benzene derivatives
GB8511894D0 (en) 1985-05-10 1985-06-19 Ici Plc Phenol derivatives
DK212786A (da) 1985-05-10 1986-11-11 Ici Plc 1,3-dioxanethere
GB8511897D0 (en) * 1985-05-10 1985-06-19 Ici Plc Carboxylic acids
WO1987002983A1 (en) * 1985-11-12 1987-05-21 Imperial Chemical Industries Plc Amide derivatives
GB8611174D0 (en) * 1986-05-08 1986-06-18 Ici Plc Amide derivatives
GB8531892D0 (en) * 1985-12-30 1986-02-05 Ici Plc Carboxylic acids
DE3603662A1 (de) * 1986-02-06 1987-08-13 Basf Ag Acetalisierte oder ketalisierte dihydroxyaldehyde, verfahren zu ihrer herstellung und diese enthaltende loesungen
GB8626296D0 (en) * 1986-11-04 1986-12-03 Ici Plc Therapeutic agents
GB8626297D0 (en) * 1986-11-04 1986-12-03 Ici Plc Pharmaceutical compositions
GB8709794D0 (en) * 1987-04-24 1987-05-28 Ici Plc Heterocyclic acids
US5248780A (en) * 1988-02-16 1993-09-28 Imperial Chemical Industries, Plc Pyridyl substituted alkenoic acid derivatives
GB8901201D0 (en) * 1988-02-16 1989-03-15 Ici Plc Pyridine derivatives
EP0346511A1 (en) * 1988-06-15 1989-12-20 Fujisawa Pharmaceutical Co., Ltd. Oxygen-containing hererocyclic compound, processes for their preparation and pharmaceutical compositions comprising them
IE81170B1 (en) * 1988-10-21 2000-05-31 Zeneca Ltd Pyridine derivatives
CN1034120C (zh) * 1988-10-21 1997-02-26 曾尼卡有限公司 制备二噁烷链烯酸衍生物的方法
GB9021571D0 (en) * 1990-10-04 1990-11-21 Ici Plc Heterocyclic acids
US5925795A (en) * 1996-09-16 1999-07-20 Zeneca Limited Processes for the preparation of aryl-β-diketones, arylpyrimidine ketones and crop protection intermediates
GB0413970D0 (en) * 2004-06-22 2004-07-28 Syngenta Participations Ag Chemical compounds
US20110178112A1 (en) * 2006-01-18 2011-07-21 Evolva Sa PPAR Modulators
EP2150111B1 (en) 2007-01-18 2016-10-19 Evolva SA Substituted 1,3-dioxanes useful as ppar modulators
CA2676439A1 (en) * 2007-01-18 2008-07-24 Evolva Sa Substituted 1,3-dioxanes and their uses
SI2850070T1 (en) * 2012-05-18 2018-01-31 Sanofi Benzo (1,3) dioxin derivatives and their use as LPAR5 antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4243592A (en) * 1979-03-12 1981-01-06 The Upjohn Company 9,11-Dideoxy-10-oxa-TXB compounds
GB8310407D0 (en) * 1982-05-12 1983-05-25 Ici Plc 1 3 - dioxan -5- ylalkenoic acids
GB8417314D0 (en) * 1984-07-06 1984-08-08 Ici Plc Carboxylic acid derivatives

Also Published As

Publication number Publication date
HU198705B (en) 1989-11-28
NZ204202A (en) 1986-05-09
AU1422383A (en) 1983-11-17
FI80027C (fi) 1990-04-10
ATE28329T1 (de) 1987-08-15
PL140463B1 (en) 1987-04-30
PL140462B1 (en) 1987-04-30
DK163431C (da) 1992-07-20
FI831664L (fi) 1983-11-13
FI831664A0 (fi) 1983-05-12
ZA833179B (en) 1984-04-25
IE55114B1 (en) 1990-06-06
KR880002001B1 (ko) 1988-10-11
JPS58222081A (ja) 1983-12-23
CS245795B2 (en) 1986-10-16
AR240817A2 (es) 1991-02-28
US4745198A (en) 1988-05-17
ES528577A0 (es) 1986-06-16
GB8310407D0 (en) 1983-05-25
FI80027B (fi) 1989-12-29
US5166377A (en) 1992-11-24
DD212515A5 (de) 1984-08-15
DK211883D0 (da) 1983-05-11
GR78138B (ko) 1984-09-26
CY1453A (en) 1989-07-21
PL140274B1 (en) 1987-04-30
ES8700250A1 (es) 1986-10-16
PH21691A (en) 1988-01-13
CA1268772A (en) 1990-05-08
NO162383B (no) 1989-09-11
PT76684A (en) 1983-06-01
DK163431B (da) 1992-03-02
AR240817A1 (es) 1991-02-28
ES528576A0 (es) 1986-10-16
ZW10083A1 (en) 1984-11-28
PT76684B (en) 1986-01-14
DE3372483D1 (de) 1987-08-20
EP0094239B1 (en) 1987-07-15
ES528575A0 (es) 1986-10-16
DD219769A5 (de) 1985-03-13
ES8700249A1 (es) 1986-10-16
PL241920A1 (en) 1985-03-26
SG57088G (en) 1989-01-27
IL68628A0 (en) 1984-05-31
US4567197A (en) 1986-01-28
EP0094239A2 (en) 1983-11-16
PL250099A1 (en) 1985-07-02
SU1277893A3 (ru) 1986-12-15
CA1268771A (en) 1990-05-08
JPH0378389B2 (ko) 1991-12-13
CA1258464A (en) 1989-08-15
IE831005L (en) 1983-11-12
ES8608507A1 (es) 1986-06-16
NO831679L (no) 1983-11-14
AU562056B2 (en) 1987-05-28
ES522331A0 (es) 1984-08-16
HK17889A (en) 1989-03-10
KE3823A (en) 1988-10-21
PL250098A1 (en) 1985-07-02
CS725784A2 (en) 1985-09-17
DK211883A (da) 1983-11-13
EP0094239A3 (en) 1984-12-12
CS245783B2 (en) 1986-10-16
CS333683A2 (en) 1985-09-17
ES8407038A1 (es) 1984-08-16
MW1583A1 (en) 1985-02-13
CA1269109A (en) 1990-05-15
CA1268771C (ko) 1990-05-08

Similar Documents

Publication Publication Date Title
KR840004739A (ko) 1,3-디옥산-5-일 알케논산의 제조방법
KR930017898A (ko) 술포닐벤질 치환 피리돈
ES550952A0 (es) Procedimiento para la preparacion de una (2-3-trans)-lactona
KR880003889A (ko) 나프탈렌 및 인단 유도체,이들 화합물을 함유하는 약제학적 조성물 및 그들의 제조 방법
KR890003786A (ko) 신규의 불포화 아미노산 화합물의 제조방법
DE3483881D1 (de) 1,3-dioxan-4-ylalkensaeure.
KR900009670A (ko) 혈소판 활성인자의 길항질인 신규 비스-아릴포스페이트 에스테르 및 그의 제조방법 및 그로써 질병을 치료하는 방법
US4126622A (en) Bicyclic lactone derivatives employed as intermediates in the synthesis of prostaglandines
US3922293A (en) Prostaglandin F-type 9-monoacylates
AU665980B2 (en) Process for producing prostaglandin E
JPS55151549A (en) Production of guanidinocaproic ester
JPS54112892A (en) Substituted imidazolidinyl-3-chloro-3-cephem-4-carboxylic acid
US4216321A (en) 3,4-Dihydropyrrolo-[1,2-a]-pyrazine and method of preparing same
SU1699992A1 (ru) Способ получени простых метиловых эфиров
JPS56108743A (en) 3-nitro-2-hydroxy-4-phenylbutyric acid derivative, its ester and preparation thereof
ATE29711T1 (de) Verfahren zur herstellung von ethylenglykol.
IE37846B1 (en) Process for preparing 6-alkoxypenicillanic and 7-alkoxycephalosporin acids
JPS55122774A (en) Production of alpha-halogen substituted-gamma-butyrolactones
JPS55162786A (en) Glyoxylic acid derivative and its preparation
JPS5750946A (en) Novel anthranilic acid derivative
JPS5564596A (en) Preparation of alkylmethyl-3-dialkoxy-propylphosphinate
JPS5795980A (en) 7-hydroxy pgi2 and its preparation
JPS57146732A (en) Preparation of perfluoroalkyl-substituted keto compound
JPS5692265A (en) Production of optically active thioglycolic acid derivative
JPS57192380A (en) Preparation of 4-alkoxy-1,3-dioxane-5-carbonitriles

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19930924

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee